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Abstract
Background: Human B cells and plasmacytoid dendritic cells (pDC) are the only cells known to
express both TLR7 and TLR9. Plasmacytoid dendritic cells are the primary IFN-α producing cells
in response to TLR7 and TLR9 agonists. The direct effects of TLR7 stimulation on human B cells is
less understood. The objective of this study was to compare the effects of TLR7 and TLR9
stimulation on human B cell function.
Results:  Gene expression and protein production of cytokines, chemokines, various B cell
activation markers, and immunoglobulins were evaluated. Purified human CD19+ B cells (99.9%,
containing both naïve and memory populations) from peripheral blood were stimulated with a
TLR7-selective agonist (852A), TLR7/8 agonist (3M-003), or TLR9 selective agonist CpG ODN
(CpG2006). TLR7 and TLR9 agonists similarly modulated the expression of cytokine and
chemokine genes (IL-6, MIP1 alpha, MIP1 beta, TNF alpha and LTA), co-stimulatory molecules
(CD80, CD40 and CD58), Fc receptors (CD23, CD32), anti-apoptotic genes (BCL2L1), certain
transcription factors (MYC, TCFL5), and genes critical for B cell proliferation and differentiation
(CD72, IL21R). Both agonists also induced protein expression of the above cytokines and
chemokines. Additionally, TLR7 and TLR9 agonists induced the production of IgM and IgG. A TLR8-
selective agonist was comparatively ineffective at stimulating purified human B cells.
Conclusion: These results demonstrate that despite their molecular differences, the TLR7 and
TLR9 agonists induce similar genes and proteins in purified human B cells.
Background
B lymphocytes play an essential role in bridging innate
and adaptive immunity. Through ligand receptor signal-
ing they differentiate into specialized cells capable of
communicating with helper T cells in order to undergo
antibody diversification, clonal expansion and immu-
noglobulin secretion. Various ligands and their corre-
sponding receptors are responsible for these signaling
events leading towards B cell activation and maturation.
Among recently discovered B cell activators, of particular
interest are the Toll-like receptors (TLRs) and their natural
agonists responsible for eliciting direct effects on human
Published: 24 July 2008
BMC Immunology 2008, 9:39 doi:10.1186/1471-2172-9-39
Received: 16 November 2007
Accepted: 24 July 2008
This article is available from: http://www.biomedcentral.com/1471-2172/9/39
© 2008 Hanten et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
Page 2 of 15
(page number not for citation purposes)
B cells. Natural TLR agonists have been shown to elicit an
innate immune response in human blood leukocytes
including peptidoglycan and lipoproteins (TLR2), dsRNA,
polyI:C (TLR3), LPS (TLR4), flagellin (TLR5), guanosine
and uridine rich ssRNA (TLR7), and oligodeoxynucle-
otides (ODNs) with CpG motifs (TLR9) [1-5]. The
Immune Response Modifier (IRM) Imiquimod (R-837)
has been shown to activate NF-κB through TLR7 while
Resiquimod (R-848) has been shown to activate NF-κB
through TLR7 and TLR8 [6,7]. Plasmacytoid dendritic
cells express TLR7 and TLR9, and are the main type 1 inter-
feron producing cells in response to IRMs and CpGs,
respectively [8-10]. B cells are the only other human leu-
kocyte subset to express both TLR7 and TLR9, and have
also been shown to be directly activated by IRMs and
CpGs [11-14]. It has been reported that memory and
naïve human B cells differentially respond to TLR7 and
TLR9 stimulation, with type I IFN being required for
TLR7-mediated polyclonal B cell expansion, TLR7 up-reg-
ulation, and B cell differentiation towards immunoglobu-
lin-producing plasma cells, but not for TLR9-mediated B
cell activation [15].
The objective of this study was to compare and contrast
the effects of TLR7- and TLR9-mediated B cell activation
by examining changes in gene and protein expression in
purified human B cells. The B cell population used in
these studies contained both naïve and memory popula-
tions of cells but was devoid of pDC. The results demon-
strate that CD19+ B cells isolated from peripheral blood
similarly respond to TLR7 and TLR9 stimulation in regard
to cytokine and chemokine expression as well as expres-
sion of selected co-stimulatory markers, Fc receptors, anti-
apoptotic genes, transcription factors, and differentiation
and proliferation genes.
Results
B cell purity and TLR basal gene expression
B cells were enriched from human PBMC by negative
selection and then purified by cell sorting. Prior to sorting,
the enriched B cell population was about 80% pure, and
the final purity after sorting was ≥99% (see Additional file
1). The expression of Toll-like receptors (TLR) in purified
B cells from 3 donors was determined by RT-PCR (Figure
1) and quantitated using the ΔΔCt method [16]. The B
cells expressed intermediate to high levels of TLR6, TLR7,
TLR9, and TLR10, and about 10-fold lower levels of TLR2
and TLR4. The expression levels of TLR3, TLR5, and TLR8
were at the lower limit of detection for the assay. The TLR
expression profiles from the 3 different donors were simi-
Relative levels of TLR2 to TLR10 mRNA expression in human B cells from 3 different donors Figure 1
Relative levels of TLR2 to TLR10 mRNA expression in human B cells from 3 different donors. Highly purified B 
cells from 3 different donors were examined for expression of the TLRs by RT-PCR. The copy number for TLR2 to TLR10 
mRNA was normalized to that for GAPDH to compare expression between donors.
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lar, and are consistent with previously published studies
[17,18]. The levels of TLR1 mRNA were not measured in
this study.
Characterization of small molecule TLR7, TLR7/8, and 
TLR8 agonists
The potency and TLR7 vs. TLR8 selectivity profiles of the
IRMs used in this study were previously demonstrated
[6,19]. At the concentrations used, 852A preferentially
activates NF-κB through TLR7, 3M-002 preferentially acti-
vates NF-κB through TLR8, and 3M-003 activates NF-κB
through both TLR7 and TLR8. For ease of discussion,
throughout this paper, 852A will be referred to as a TLR7
agonist, 3M-002 will be referred to as a TLR8 agonist, 3M-
003 will be referred to as a TLR7/8 agonist, and CpG2009
will be referred to as a TLR9 agonist. However, these
names should not be construed as indicating absolute
selectivity, since at higher concentrations, the preferential
selectivity breaks down, and 852A can activate through
TLR8 while 3M-002 can activate through TLR7. Therefore,
as was reported in other systems [20], the concentration of
test compound used must be carefully selected to observe
and correctly interpret the desired effects. The minimum
effective concentration required to activate NF-κB in TLR-
transfected HEK293 cells is shown in Table 1, illustrating
the TLR selectivity of the various small molecule TLR ago-
nists at the concentrations used in this study.
TLR agonist induced gene expression
The expression profiles of cytokine, chemokine, prolifera-
tion, differentiation, co-stimulatory, Fc receptor, tran-
scription factor, and anti-apoptotic genes were evaluated
in purified B cells at 2, 8, and 24 hr following stimulation
with TLR agonists. The time course of gene expression for
one representative donor is illustrated (see Additional file
2 and Additional file 3). Gene expression was predomi-
nantly maximal at either 2 or 8 hours post treatment. The
maximum gene expression for one representative donor is
illustrated in Figure 2 as a heat map. The maximum gene
expression data for all 3 donors are summarized in Table
2.
Cytokine, chemokine and pro-inflammatory mediator genes
In general, the gene expression profiles of B cells treated
with 3 μM 852A, 1 μM 3M-003, or 3 μM CpG2006 were
similar in regard to the specific genes that were modu-
lated. Figure 2 shows a 2 way hierarchical clustering of the
log 2 transformed fold change of genes altered in expres-
sion. The figure shows that 852A, 3M-003 and CpG2006
cluster together, indicating a similar gene expression pro-
file. However, the magnitude of modulation for most
genes was greater in B cells treated with the TLR7/8 ago-
nist 3M-003 and the TLR9 agonist CpG2006, compared to
those treated with 852A, at the tested concentrations. For
example, CCL3 (MIP1α), CCL4 (MIP1β), and IL6 genes
were 2 to 5 times higher in expression in 3M-003- or
CpG2006-treated B cells as compared to those treated
with 852A. In other instances, however, the levels of gene
modulation by 852A, 3M-003, and CpG2006 were simi-
lar. For example, TNFα and TNFβ (Lymphotoxin alpha,
LTA) genes were equally modulated by 852A, 3M-003 or
CpG 2006 in treated B cells, where all three TLR agonists
resulted in 3- to 5-fold more LTA than TNFα gene expres-
sion. Note that the inactive analog, 3M-006, which was
denoted as inactive because it did not induce cytokine
production from human PBMC in contrast to 3M-001,
3M-002, and 3M-003 [6], was comparatively inactive for
all genes evaluated in this study.
Interestingly, some genes were modulated by the TLR8
agonist 3M-002, which is likely due to residual NF-κB acti-
vation through TLR7. In comparison to the magnitude of
gene induction by TLR7, TLR7/8, or TLR9 agonists, the
TLR8 agonist generally induced lower levels of the same
genes. However, the exceptions were MIP3α, IL1β, and
COX2, which were induced in at least 2/3 of the donors
by the agonists that can activate NF-κB through TLR8
(3M-002 and 3M-003) but not by the TLR7-selective ago-
nist 852A or the TLR9 agonist CpG2006. Based on the
Table 1: Potency of small molecule TLR agonists in activating TLR7- and TLR8-mediated NF-κB activity in transfected human HEK293 
cells.
Compound Minimum effective concentration (MEC, μM) for NFκB activation (a) TLR selectivity (b)
TLR7 TLR8
3M-006 Inactive (100) Inactive (100) None
3M-003 0.1 1 TLR7/8 @ 1 μM
852A 3 100 TLR7 @ 3 μM
3M-002 10 1 TLR8 @ 5 μM
(a) Transfection of HEK293 cells with TLR7 or TLR8, and assessment of IRM-induced NFκB activation was performed as previously described [6]. 
Potency is defined as the concentration required to induce an increase in NFκB activation. MEC, minimal effective concentration, is the lowest 
concentration required to observe a 2-fold increase above the vehicle control.
(b) Selectivity is defined as preferential signaling through TLR7 or TLR8 at a specified concentration of the TLR agonists.BMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
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purity of the CD19+ population, it is unlikely that cells
known to respond to TLR8 agonists, such as monocytes or
conventional DC, are responsible for the induction of
these proinflammatory genes. However, we can not rule
out the possibility that low numbers of contaminating
monocytes or conventional (myeloid) DC were responsi-
ble for the induction of some genes, such as IL-1β, since
3M-002 strongly induces IL-1β production from these
cells (6). Another possibility is that 3M-002 may drive
production of cytokines like IL-1β through interaction
with other systems such as the cryopyrin pathway.
Because TLR7 and TLR9 agonists are known to robustly
stimulate expression of type I IFNs and IFN-inducible
genes in pDC [8,9,21-24], it was essential to eliminate
pDC from the cell preparation in order to characterize the
effects of these TLR agonists on human B cells. To deter-
mine if functional pDC were contaminating the B cell
population, the expression of type I IFN and IFN-induci-
ble genes that are indicative of pDC activation (IFNα 2,
MX1, ISG15, TLR7 and TLR9) were evaluated following
stimulation with the TLR agonists (Table 3). None of
these genes were consistently induced by the TLR agonists,
indicating that functional pDC were not present in the B
cell population. However, some low-level of inconsistent
gene activation was observed between donors, which is
probably due to variations in assay conditions. B cell
secreted protein values, assayed by Luminex, also con-
firmed that there was no protein production of IFN alpha
or the type I IFN-inducible IP10 (data not shown).
Co-stimulatory marker and Fc receptor genes
In addition to cytokine and chemokine gene expression,
TLR7, TLR7/8, and TLR9 agonists directly induced the
expression of co-stimulatory genes (CD80, CD86, CD40
and CD58) in human B cells (Figure 2 and Table 2). Such
markers of activation are considered important for anti-
gen presentation and stimulation of T cells. Additionally,
two Fc receptors were modulated by TLR7, TLR7/8, and
TLR9 agonists. Specifically, CD23 (FCER2) was up-regu-
Table 2: Gene expression profile of human B cells modulated by TLR7, 8, or 9 agonists from 3 different donors (maximum fold-change 
through a 2, 8, 24 hour time course).
Gene Alias 3M-006 3M-002 852A 3M-003 CpG 2006
D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3
FCGR2B CD32 -1.2 -1.7 -1.2 -1.3 -1.9 -1.3 -2.6 -4.7 -2.1 -7.4 -19.1 -8.4 -6.7 -22.8 -8.6
GBP2 GBP2 -1.1 -1.5 1.0 -1.1 -1.9 1.0 -2.8 -5.0 -2.3 -3.5 -13.4 -7.1 -2.6 -1.7 -1.8
CD72 Ly-19 -1.5 1.2 1.4 -1.1 -1.2 1.4 -3.2 -3.9 -1.8 -5.1 -9.1 -4.4 -3.5 -5.8 -2.9
GAPDH GAPDH 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0*
IL12B IL12p40 -1.1 1.3 1.2 8.5 1.5 1.1 9.1 -1.1 2.5 16.1 1.3 3.7 11.4 -1.2 1.6
FCER2 CD23 -1.1 -1.4 -1.3 1.6 1.4 1.5 3.1 1.7 2.9 7.0 2.3 5.4 3.5 1.1 3.7
CCL20 MIP3a -1.2 -1.2 1.2 52.3 6.7 1.3 2.9 -1.6 1.0 28.6 2.6 1.4 -2.9 -2.1 1.0
IL-1B IL1F2 -1.7 -1.6 -1.8 31.1 8.2 29.1 2.6 1.7 2.8 28.8 5.4 9.8 3.9 -1.7 3.2
COX-2 PTGS2 -1.2 -2.8 1.3 21.7 5.0 2.0 -2.7 2.0 2.7 16.8 3.6 5.6 4.9 8.3 2.2
CD86 B7-2 -1.2 -1.2 1.2 1.2 1.3 1.3 2.1 2.3 2.3 2.8 5.0 4.1 1.6 3.8 1.9
CD40 TNFRSF5 1.1 1.1 1.1 1.6 1.6 1.6 3.7 2.6 3.1 6.1 4.7 6.0 4.7 4.0 3.0
FOS c-fos 1.1 1.4 1.6 -1.3 1.6 1.8 -2.0 2.8 2.7 -3.7 4.7 6.1 -2.7 -2.0 -1.6
GOS-2 RP1 -1.4 -1.4 2.0 2.3 2.0 2.6 3.1 2.7 4.4 6.3 4.5 10.0 5.3 5.1 7.5
NFKB1A IKBA 1.1 1.5 1.4 1.9 1.7 2.2 3.8 3.8 4.2 4.8 4.2 6.6 4.0 4.2 5.4
TR3 TNFRSF25 1.3 1.8 1.6 1.2 1.9 2.1 1.5 4.0 3.5 -2.7 3.2 5.6 2.0 3.6 -1.5
CD58 LFA3 1.1 1.2 1.2 1.3 1.5 1.6 2.0 3.8 3.2 3.3 4.8 5.0 3.2 5.2 5.5
IL21r NILR 1.3 1.4 1.3 1.7 2.2 2.2 3.5 4.7 5.4 4.9 5.7 6.7 4.0 5.1 6.3
MYC c-myc -1.2 1.4 1.4 1.6 1.7 1.9 2.1 3.7 3.2 3.5 7.0 10.7 3.6 12.3 8.1
CD80 B7-1 1.2 1.4 1.2 2.0 1.9 1.8 3.9 4.8 3.8 7.3 8.6 8.1 6.1 6.9 6.4
TNFa TNFSF2 -1.2 1.4 1.2 3.1 2.2 1.7 9.5 6.9 7.7 14.9 10.3 16.2 13.8 11.8 7.0
IL1a IL1F1 -1.7 1.5 1.2 2.5 4.5 1.5 4.0 4.3 2.8 5 . 71 1 . 46 . 84 . 61 1 . 72.9
CCL4 MIP1b 1.4 1.0 1.2 3.3 2.3 3.0 6.1 7.1 5.7 10.8 10.9 32.6 22.3 38.6 37.4
CCL3 MIP1a 1.2 1.2 1.5 4.5 2.4 2.9 11.4 10.0 10.1 18.9 15.6 45.6 39.3 45.6 62.3
BFCL2L1 Bcl-xl -1.3 -1.1 1.3 1.9 1.8 2.1 4.5 8.3 6.4 6.1 21.7 15.1 5.1 12.8 9.2
DSP2 PAC1 1.3 1.5 1.2 1.2 2.8 2.0 2.3 10.8 4.6 4.0 16.1 18.3 3.7 13.5 5.0
LTA TNFSF1 1.0 1.3 1.3 6.1 2.5 2.5 63.0 18.8 24.3 85.8 18.5 32.0 55.5 22.1 24.9
TCFL5 E2BP1 -1.2 1.3 1.2 1.6 3.1 2.0 9.7 17.7 9.4 22.6 25.2 24.9 16.3 23.5 18.7
IL-6 IFNB2 1.9 2.4 1.0 7.0 4.7 6.1 24.9 25.6 40.4 70.8 51.3 71.9 58.9 59.4 53.2
(a) normal text = subjectively assigned nominal to low fold change (-3.4 to 3.4).
(b) bold text, negative values = subjectively assigned moderate fold suppression (-23.0 to -3.5).
(c) bold text, positive values = subjectively assigned moderate to high fold increase (3.5 to 86.0).
(d) text with * = GAPDH, house keeping gene as a reference.BMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
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Profile of gene expression changes in human B cells stimulated with agonists of TLR7, 8 or 9 Figure 2
Profile of gene expression changes in human B cells stimulated with agonists of TLR7, 8 or 9. Purified B cells were 
stimulated with the indicated IRM or with CpG2006. Gene expression changes were assessed by quantitative real time RT-
PCR at 2, 8 or 24 hours after stimulation. The log2 of the maximum fold change over the time course from 2 to 24 hours for 
1 representative donor is shown. Hierarchical clustering was performed as described in methods.
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lated by these TLR agonists, while CD32 (FCGR2B) was
down-regulated. CD23 is an important molecule for B cell
activation and growth, as well as being a low-affinity
receptor for IgE [25]. CD32 serves as an inhibitory Fc
receptor for IgG and appears to co-aggregate with B cell
receptor-bound antigen resulting in inhibition of B cell
activation [26]. Thus, decreased expression of the CD32
inhibitory gene is associated with heightened antigen
presentation, proliferation and antibody production.
Interestingly, the degree of modulation for these genes
was 2 to 5 times more in CpG2006-treated B cells as com-
pared to B cells treated with 852A, while they were com-
parable in B cells exposed to 3M-003, which is a more
potent activator of TLR7.
Proliferation and differentiation
TLR7, TLR7/8, and TLR9 agonists induced mRNA expres-
sion of IL21R and myc, and to a lesser extent, fos.
Although these genes are associated with differentiation
or proliferation, stimulation of B cells with TLR7 or TLR7/
8 agonists resulted in minimal proliferation compared to
stimulation with CpG2006 (data not shown), which is
consistent with a previous report [15]. The anti-apoptotic
gene BCL-xL was also upregulated by 852A, 3M-003, or
CpG2006, which is consistent with a previous report that
the TLR7/8 agonist R-848 enhanced human pDC survival
[8]. Induction of anti-apoptotic gene expression in pDC
upon stimulation with 852A has also been described [24].
Overall, the data suggest that TLR7- and TLR9-mediated B
cell activation engages differentiation, proliferation, and
survival pathways within 24 hr after TLR stimulation.
Transcription factors
A number of transcription factors and related signaling
proteins were also modulated by TLR7- or TLR9-mediated
B cell stimulation. NFKB1A, TCFL5, TR3, and DSP2 were
up-regulated following TLR7 and TLR9 activation, while
GBP2 was down-regulated. Again, the inactive analog 3M-
006 and the TLR8 agonist had minimal effects on these
transcription factor genes. IKBA (NFKB1A) is one member
of the IκB family that functions to inhibit NFκB transcrip-
tional activity (reviewed in [27]). TCFL5 is a basic helix-
loop-helix transcription factor whose function is unclear
[28]. TR3 is an orphan nuclear receptor that negatively or
positively regulates gene expression [29]. DSP2 is member
of the dual-specificity-phosphatase family that may nega-
tively regulate STAT3 signaling [30] and may indirectly
modulate other transcriptional regulators by inactivating
p38 or JNK [31]. In general, TLR7- and TLR9-mediated
regulation of the expression of mRNA for various tran-
scription factors and signaling molecules is consistent
with the modulation of cytokine, chemokine, prolifera-
tion, differentiation, co-stimulatory, Fc receptor and cell
survival genes.
TLR7- and TLR9-mediated cytokine production
In order to confirm the changes in mRNA expression,
induction of secreted protein production from the B cells
was measured by multiplex immunoassay. Comparisons
were made between different treatments relative to the
vehicle control. Figures 3, 4, 5 compare mRNA expression
for IL6, CCL3 (MIP1α), and CLL4 (MIP1β) at 2, 8, and 24
hr with protein production at 8 and 24 hr after TLR ago-
nist stimulation of B cells.
TLR7, TLR7/8 and TLR9 agonists induced increases in
both gene expression and protein production for IL6,
CCL3 and CCL4. Expression of mRNA for all three genes
was significantly increased at 2 and 8 hours after stimula-
tion. By 24 hours after stimulation, mRNA for CCL3 and
CCL4 had returned to baseline in B cells stimulated with
852A and 3M-003, but was still somewhat elevated in B
cells stimulated with the TLR9 agonist. IL-6 mRNA exhib-
ited a different temporal pattern, and was still signifi-
cantly elevated at 24 hours after stimulation with TLR7,
TLR7/8 and TLR9 agonists. Maximal protein production
for IL-6, CCL3 and CCL4 was 5 to 50 times greater than
the corresponding vehicle control group at 8 and 24 hours
Table 3: Interferon and interferon-inducible genes in human B cells were minimally and inconsistently modulated by TLR7, 8, or 9 
agonists from 3 different donors (maximum fold-change through a 2, 8, 24 hour time course).
Gene Alias 3M-006 3M-002 852A 3M-003 CpG 2006
D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3
GAPDH GAPDH 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0* 1.0*
IFNa-2 IFNa-2 2.6 1.7 1.5 3.5 1.8 1.4 3.0 -1.3 1.2 -2.2 -1.5 -1.2 4.0 -1.7 -1.2
ISG15 ISG15 1.6 1.3 1.2 1.9 1.1 1.5 1.2 1.5 1.8 3.0 -2.7 2.3 -1.5 -2.2 -1.5
MX1 MX1 1.3 -1.2 1.3 1.7 -1.5 1.1 1.5 -2.3 -1.6 6.8 -3.3 -4.2 -3.9 -3.4 -4.3
TLR7 TLR7 1.5 -1.2 1.6 1.2 -1.3 1.3 -2.8 -2.7 -1.6 -2.9 -2.1 -4.3 -3.5 -6.7 -4.5
TLR9 TLR9 - 1 . 3- 1 . 2- 1 . 11 . 0 - 1 . 3- 1 . 1- 1 . 9- 1 . 5- 1 . 4- 3 . 1-3.9 -2.3 -3.2 -3.0 -1.7
The data represented in Table 3 and Table 2 are from the same experiment, but were separated into 2 different tables for illustration purposes.
(a) normal text = subjectively assigned nominal to low fold change (-3.4 to 3.4).
(b) bold text, negative = subjectively assigned moderate fold suppression (-23.0 to -3.5).
(c) bold text, positive = subjectively assigned moderate to high fold increase (3.5 to 86.0).
(d) text with * = GAPDH, house keeping gene as a reference.BMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
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after induction by TLR7, TLR7/8 or TLR9 agonists, with
852A exhibiting somewhat less protein production than
the other two stimuli. The TLR8 agonist induced a maxi-
mum increase of <7-fold in gene expression and < 3 times
greater than the corresponding vehicle control in protein
production, while 3M-006 induced no significant changes
in mRNA or protein for IL-6, CCL3 and CCL4. There was
a variable level of secreted IL-8 by treatment with the TLR
agonists, ranging from ~20–150 pg/ml. Interestingly,
secreted protein levels of IL1β (~50–350 pg/ml), IL2
(~40–60 pg/ml) and IL2R (~20–30 pg/ml) were observed
exclusively after treatment with CpG 2006. Other
cytokines and chemokines examined (IL1RA, IL4, IL5,
IL7, IL10, IL12p40, IL13, IL15, IL17, TNFα, IFNα, IFNγ,
GM-CSF, IP10, MIG, Eotaxin, RANTES, and MCP1) were
not consistently increased by the TLR agonists (data not
shown).
IRMs and CpG2006 induce IgM and IgG antibody 
production in human B cells
The B cell population in peripheral blood is comprised of
naïve, memory and plasma cells. When B cells were cul-
tured for 10 days in the presence of 852A, 3M-003 or CPG
2006, they differentiated, at least in part, into antibody
producing cells. Figures 6A &6B illustrate the levels of
total IgM and IgG production from B cells treated with
various concentrations of one of the IRMs or CPG 2006. B
cells cultured with the lowest concentration of CpG tested
produced maximal amounts of IgM and IgG. In contrast,
higher concentrations of 3M-003 or 852A were required
Changes in mRNA and protein for IL6 Figure 3
Changes in mRNA and protein for IL6. Purified B cells from 3 different donors were stimulated with the indicated IRM or 
with CpG2006 for 2, 8 or 24 hours, and then were harvested for mRNA analysis. The fold change in gene expression at each 
time point, normalized to vehicle control, is shown for IL6 (Panel A). Conditioned media from the stimulated cells were col-
lected at 8 and 24 hours after stimulation for analysis of protein production. The amount of secreted IL6 (in pg/ml) is shown in 
Panel B. The concentrations of the TLR agonists were: 3M-006, 5 μM; 3M-003, 1 μM; 852A, 3 μM; 3M-002, 5 μM; CpG 2006, 3 
μM.
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Changes in mRNA and protein for CCL3 (MIP1α) Figure 4
Changes in mRNA and protein for CCL3 (MIP1α). Purified B cells from 3 different donors were stimulated with the 
indicated IRM or with CpG2006 for 2, 8 or 24 hours, and then were harvested for mRNA analysis. The fold change in gene 
expression at each time point, normalized to vehicle control, is shown for CCL3 (MIP1α), (Panel A). Conditioned media from 
the stimulated cells were collected at 8 and 24 hours after stimulation for analysis of protein production. The amount of 
secreted CCL3 (MIP1α) (in pg/ml) is shown in Panel B. The concentrations of the TLR agonists were: 3M-006, 5 μM; 3M-003, 1 
μM; 852A, 3 μM; 3M-002, 5 μM; CpG 2006, 3 μM.
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to achieve maximal antibody production. B cells treated
with optimal concentrations of the IRMs produced com-
parable amounts of IgM as those stimulated with the TLR9
agonist. However, they produced significantly more IgG
than B cells exposed to CpG2006.
Discussion
In this study, highly purified human B cells (≥99%), con-
taining both naïve and memory populations, were
directly activated through TLR7 or TLR9 and changes in
gene and protein expression were examined. Overall,
Changes in mRNA and protein for CCL4 (MIP1β) Figure 5
Changes in mRNA and protein for CCL4 (MIP1β). Purified B cells from 3 different donors were stimulated with the 
indicated IRM or with CpG2006 for 2, 8 or 24 hours, and then were harvested for mRNA analysis. The fold change in gene 
expression at each time point, normalized to vehicle control, is shown for CCL4 (MIP1β) (Panel A), Conditioned media from 
the stimulated cells were collected at 8 and 24 hours after stimulation for analysis of protein production. The amount of 
secreted CCL4 (MIP1β) (in pg/ml) is shown in Panel B. The concentrations of the TLR agonists were: 3M-006, 5 μM; 3M-003, 1 
μM; 852A, 3 μM; 3M-002, 5 μM; CpG 2006, 3 μM.
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Antibody production from differentiated B cells Figure 6
Antibody production from differentiated B cells. Purified B cells were cultured for 10 days in the presence of the indi-
cated concentrations of an IRM or CpG2006. Conditioned media from these cultures was analyzed for production of IgM 
(Panel A) or IgG (Panel B). Data from a representative donor are shown.
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there was comparable gene expression and secreted
cytokine profile for human B cells treated with the TLR7
agonist 852A (3.0 μM) or the TLR7/8 agonist 3M-003 (1.0
μM) versus the TLR9 agonist CpG 2006 (3.0 μM). TLR7 or
TLR9 activation in B cells also induced IgM and IgG anti-
body secretion in a dose dependent manner. Furthermore,
852A, 3M-003 or CpG 2006 modulated co-stimulatory
molecule and Fc receptor expression, thus priming B cells
for interactions with other immune cells (e.g. dendritic
cells, T cells, etc.). The similarity of gene expression
changes induced by TLR7 and TLR9 agonists is not surpris-
ing, considering that both receptors use a common signal-
ing pathway mediated by MyD88. A summary of the
effects of TLR7 or TLR9 stimulation on human B cell gene
expression and function is shown in Figure 7.
The biggest difference between B cell responses induced
by TLR7 and TLR9 agonists was observed in immunoglob-
ulin production. Much lower concentrations of TLR9 ago-
nists were able to induce production of IgM and IgG,
while peak immunoglobulin production was observed at
higher concentrations of TLR7 agonists. The maximal
amount of IgM produced by TLR7 or TLR9 agonists was
comparable, despite the difference in concentrations
needed to induce IgM production. However, TLR7 ago-
nists induced significantly more IgG than TLR9 agonists.
The mechanism(s) behind these differences has(have) not
yet been elucidated. However, the differential antibody
repertoire induced by TLR7 and TLR9 agonists may have a
profound effect on an individual's response to infection
and long-term immunity.
Despite overall similarity, the induction of expression of
mRNA for some genes (e.g. IL6, CCL3 (MIP1α), CCL4
(MIP1β)) was more robust in response to stimulation
with CpG 2006 at the dose tested, than with the IRMs that
activated TLR7. An additional difference between B cells
stimulated with TLR9 or TLR7 agonists was the observa-
tion that CpG 2006-treated B cells secreted detectable lev-
els of IL1β, IL2 and IL2R protein, whereas 852A- or 3M-
003-treated B cells did not. This could be due to the fact
Functional consequences of TLR7 and TLR9 regulated gene expression in human B cells Figure 7
Functional consequences of TLR7 and TLR9 regulated gene expression in human B cells. Stimulation of B cells 
with agonists of TLR7 or TLR9 induces changes in gene expression and protein production that effect B cell function.
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that our pure B cell population contained more naïve cells
which respond to CpG and not to TLR7 agonists.
It was reported that naïve B cells express TLR9 and are
responsive to CpG 2006, yet do not express TLR7 and are
unresponsive to IRMs [15]. That study also showed that
type 1 interferons from plasmacytoid dendritic cells
(PDCs) are responsible for the up-regulation of TLR7 on
naïve B cells, thus enabling their activation by TLR7 lig-
ands such as IRMs [15]. In contrast with naïve B cells,
memory B cells exhibited some responsiveness to TLR7
stimulation in the absence of type I IFN, but stimulation
of their proliferation was amplified by addition of IFN-α
[15]. Although the B cells used in our study were highly
purified, no attempt was made to separate the naïve B cells
from the memory B cells, and the population used in
these studies was not characterized for the relative abun-
dance of these two phenotypes. However, based on pub-
lished data on young and elderly individuals, the
proportion of memory B cells was probably 15–30% [32].
If we assume that the prior report on lack of TLR7 expres-
sion by naïve B cells [15] is correct, then the observation
that changes in B cell gene expression was directly acti-
vated by 852A or 3M-003 in the absence of pDC or type I
IFN suggests that the responses monitored in this report
were from the memory B cell population. The limited
induction of B cell proliferation by the TLR7 agonists is
consistent with the previously reported modest stimula-
tion of memory B cells in the absence of IFN-α [15].
The data indicate that CD23 was up-regulated by the TLR
agonists, while CD32 was down-regulated, and the degree
of modulation for these genes was 2 to 5 times more in
CpG2006-treated B cells as compared to B cells treated
with 852A, but not 3M-003. This difference could result
from the observation that 3M-003 is a more potent activa-
tor of TLR7. Changes in these genes may have a significant
effect on B cell responses, since CD23 and CD32 are
important molecules for B cell activation, antigen presen-
tation, proliferation, and antibody production [25,26].
Thus, it is expected that decreased expression by 852A,
3M-003 or CpG 2006 of the CD32 inhibitory molecule
may cause heightened antigen presentation and antibody
production.
It has been reported that TLR7-deficient, lupus-prone
mice failed to generate antibodies to RNA-containing
antigens. TLR9 and TLR7 also had modulatory effects on
clinical disease in lupus-prone mice. In the absence of
TLR9, autoimmune disease was exacerbated. In contrast,
TLR7-deficient mice had ameliorated disease. These find-
ings reveal opposing inflammatory and regulatory roles
for TLR7 and TLR9, despite similar tissue expression and
signaling pathways. These results have important implica-
tions for TLR-directed therapy of autoimmune disease
[33,34]. Another study showed that a dual inhibitor of
TLR7 and 9, immunoregulatory sequence (IRS) 954, can
prevent progression of disease when injected in the lupus
prone (NZB×NZW)F1 mice [35]. While it is difficult to
reconcile all these findings, it is tempting to speculate that
differential expression of TLR7 and TLR9 in naïve vs.
memory cells may have an influence on the immune
response to self antigens such as RNA.
CpGs were reported to upregulate TRAIL on B cells in
PBMC and thereby enhance their ability to kill tumor cells
[36]. Evidence also suggests that combinatorial expression
of certain cytotoxic TNF family ligands (TRAIL, TNF alpha,
Lymphotoxin (LT-α1β2), Fas ligand) on dendritic cells
elicits tumoricidal activity [37]. 852A, 3M-003 and CpG
2006 all induced TNF and LTA expression in B cells, which
raises the possibly of inducing anti-tumor activity. In
addition to its apoptotic effects on certain tumor cells, the
secreted form of LTA is believed to play an important role
in lymphoctye homing and the development of lymph
nodes and spleen [38,39]. Thus, TLR7 or TLR9 agonists
may promote anti-tumor activity directly or via other
immune mechanisms.
Conclusion
Our studies demonstrate that human B cells are directly
activated by the TLR7 agonist 852A and the TLR7/8 ago-
nist 3M-003 in a similar fashion to the TLR9 agonist CpG
2006. The findings in this report support the utility of
852A or a TLR7/8 agonist like 3M-003 in the treatment of
cancer or other conditions in which the activation of B
cells may be desirable.
Methods
TLR agonists
Small molecule imidazoquinoline TLR7, TLR8, and TLR7/
8 agonists: 852A, N-[4-(4-amino-2-ethyl-1H-imi-
dazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;
formula, C17H23N5O2S; m.w., 361; 3M-002, 2-pro-
pylthiazolo [4,5-c]quinolin-4-amine; formula,
C13H13N3S; m.w., 243; 3M-003, 4-amino-2-(ethoxyme-
thyl)-,-dimethyl-6,7,8,9-tetrahydro-1H-imidazo [4,5-
c]quinoline-1-ethanol hydrate (formula, C17H26N4O2;
m.w., 318) and an inactive small molecule TLR7/8 ana-
log, 3M-006, were prepared by 3M Pharmaceuticals. All
imidazoquinolines were prepared in DMSO (sterile cell
culture grade; Sigma-Aldrich) at a concentration of 10
mM and stored in aliquots at 4°C. Phosporothioate-pro-
tected CpG oligonucleotide 2006 (CpG2006, 5'-
TCGTCGTTTTGTCGTTTTGTCGTT-3') was obtained from
(Genosys, Woodlands, TX).
Isolation and treatment of human peripheral blood B cells
Human peripheral blood mononuclear cells (PBMCs)
were obtained from healthy volunteers from AllCells,BMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
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LLC. (Berkeley, CA) and Memorial Blood Centers (Minne-
apolis, MN). PBMCs were isolated using a Ficoll-paque
PLUS® (Amersham Biosciences, Piscataway, NJ) density
gradient as recommended by the manufacturer. The iso-
lated PBMC were washed once with Dulbecco's Phos-
phate Buffered Saline without Ca2+ or Mg2+ (Biosource)
and resuspended in MACS Running Buffer (pH 7.2 Phos-
phate Buffered Saline + BSA + EDTA + 0.09% Azide). B
cells were enriched using a B cell isolation kit II (Miltenyi
Biotech, Auburn, CA) following the manufacturer's
instructions. Granulocytes, platelets, erythroid cells and
mononuclear cells were labeled with a cocktail of bioti-
nylated CD2, CD14, CD16, CD36, CD43 and CD235a
(Glycophorin A) antibodies and subsequently labeled
with Anti-Biotin MicroBeads. The positively selected cells
were removed using AutoMACS (depletion program per-
formed in triplicate). The enriched, untouched CD19+
population was stained with a cocktail of fluorescently-
labeled antibodies (CD19-PE, BD Biosciences, BDCA-4-
APC, Miltenyi Biotech) and DAPI (Molecular Probes, Inv-
itrogen Corp, Carlsbad, CA) for dead-cell discrimination
and sorted to ≥99% purity on a BD FACSAria by gating on
the CD19+ BDCA-4- DAPI- cells (cell purity histogram of 1
representative donor, (see Additional file 1). Note that
doublets were removed by first gating on lymphocytes
(FSC vs SSC) and then discriminating against doublets on
the basis of FSC-A vs SSC-A and then onto SSC-H vs SSC-
W. The purified B cells (a mixture of naïve and memory
cells) generated by the combination of immunomagnetic
bead depletion followed by flow sorting were free of con-
taminating pDC.
The purified B cells were resuspended in X-vivo 20
medium (BioWhitaker serum free medium, Cambrex Bio
Science Walkersville Inc., Walkersville, MD) at 2–3 × 106
cells/mL and rested 1 hr at 37°C prior to stimulation. For
gene expression studies and cytokine and chemokine
determination, B-cells were stimulated with 3.0 μM 852A
(TLR7 selective), 5.0 μM 3M-002 (TLR8 selective), 1.0 μM
3M-003 (TLR7/8 agonist) or 5.0 μM 3M-006 (inactive
analog) dissolved in dimethyl sulfoxide (DMSO, Sigma
Chemical) or the same volume of DMSO as the vehicle
control, or 3.0 μM CpG 2006 (TLR9 selective) dissolved in
tissue-culture grade, endotoxin-free distilled H2O. Tissue
culture supernatants and cellular mRNA were collected 2,
8, and 24 hour following TLR stimulation. For immu-
noglobulin determination, purified B cells were cultured
in RPMI 1640 with 10% heat-inactivated FBS, 1% penicil-
lin/streptomycin and incubated with 852A, 3M-002, 3M-
003, 3M-006 or CpG2006 (0.03, 0.1, 0.3, 1.0, 10.0, 30.0
μM), in 5% CO2 for 10 days, at which time the superna-
tant levels of IgG and IgM were determined by ELISA.
Note that TLR selectivity was defined as previous
described in genetic reconstitution studies using TLR-
transfected HEK293 cells (6). In brief, HEK cells were co-
transfected with individual human TLRs and a NFκB-luci-
ferase reporter construct. A TLR agonist was defined as a
molecule that could activate NFκB in HEK293 cells that
expressed a TLR. Selectivity was defined as the concentra-
tion of a given agonist that induced NFκB activation in
HEK cells transfected with only one of the TLRs (TLR7,
TLR8, or TLR9). As an example, a TLR7-selective agonist
activated NFκB at the tested concentration in TLR7 trans-
fected cells, but not in TLR8 or TLR9 transfected cells.
Cytokine analysis
Tissue culture supernatants were frozen at -20°C and later
assayed for cytokines and chemokines using a Human
Cytokine Twenty-Five-Plex Antibody Bead Kit for
Luminex xMAP™, and Luminex™ 100 System (Biosource,
Camarillo, CA and Luminex Corporation, Austin, TX).
IgG and IgM were measured by ELISA (Zeptometrics Buf-
falo, NY).
RNA stabilization and reverse transcription
RNA was preserved by the direct addition of 400 μl of RLT
buffer from the Qiagen RNAeasy kit (Qiagen Inc., Valen-
cia CA) to the cell pellet. Stabilized RNAs were frozen at -
20°C until they could be purified using the RNAeasy kits
(Qiagen). Purified RNA was then reverse transcribed using
SuperScript Double Stranded cDNA Synthesis kit (Invitro-
gen Corp, Gaithersburg MA), using random hexamer
primers.
Quantitative polymerase chain reaction
Quantitative real-time Polymerase Chain Reaction, RT-
PCR was conducted using an open 96 well plate format
with ABI validated Taqman® Gene Expression Assays and
custom Taqman® Low Density Arrays (Applied Biosys-
tems, Foster City CA). Samples were run in duplicate for
the 96 well plate format. PCR cycling conditions were
50°C for 2 minutes, 95°C for 10 minutes, then 35 cycles
of 95°C for 15 seconds, and 60°C for 1 minute using an
ABI PRIZM 7900HT Sequence Detection System (Applied
Biosystems, Foster City CA). Low Density Arrays con-
tained Taqman®  reagents for 23 different genes and
GAPDH as a reference. Each reagent was run in duplicate
for each sample. PCR cycling conditions were 50°C for 2
minutes, 95°C for 10 minutes, then 35 cycles of 95°C for
30 seconds, and 60°C for 1 minute using an ABI PRIZM
7900HT Sequence Detection System (Applied Biosystems,
Foster City CA). The instrument software calculated the
number of cycles (Ct) required for the accumulated signal
to reach a designated threshold value at least 10 standard
deviations greater than the baseline. The Ct value is then
proportional to the number of starting copies of the target
sequence. Relative quantitation of gene expression was
performed using the ΔΔCt method as described in User
Bulletin #2, PE Applied Systems [16]. The fold modula-
tion was calculated relative to the vehicle control throughBMC Immunology 2008, 9:39 http://www.biomedcentral.com/1471-2172/9/39
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the same time course. The TLR basal level of gene expres-
sion was determined by converting Ct values into a rela-
tive copy number using the following assumptions; a copy
number of zero is set at 35 cycles, and GAPDH expression
as a percentage of total transcripts is consistent from
donor-to-donor. The relative copy number was standard-
ized using 2 ng per reaction.
Gene cluster analysis
Hierarchical cluster analysis was performed with Spotfire
DecisionSite-8.1 for Functional Genomics (Spotfire Inc,
Somerville, Massachusetts) using the Unweighted Pair-
Group Method with Arithmetic mean (UPGMA) and the
Euclidean similarity measure.
Abbreviations
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